Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study

Yu, Siqing; Framme, Carsten; Menke, Marcel Nico; Berger, Lieselotte Erika; Zinkernagel, Martin; Munk, Marion Rohit; Wolf, Sebastian; Ebneter, Andreas (2020). Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study. Scientific Reports, 10(1), p. 4948. Nature Publishing Group 10.1038/s41598-020-61835-0

41598_2020_Article_61835.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

We aimed to evaluate the neuroprotective efficacy of rasagiline in pseudophakic patients who had surgery for macula-off rhegmatogenous retinal detachment (RRD). This was a 6-month, prospective, randomized, double-blind, placebo-controlled pilot study. Patients presenting with acute macula-off RRD were recruited and randomized 1:1 to receive rasagiline 1mg/day or placebo for 7 days. Best-corrected visual acuity (BCVA) and optical coherence tomography were acquired 1 day before as well as 2 days, 3 weeks, 3 months and 6 months after surgery. We screened 26 patients with RRD whereof 23 were eventually included and randomized. The primary outcome was final BCVA. Secondary outcomes included central retinal thickness (CRT) and adverse events (AE). We evaluated photoreceptor cells (prc) recovery through morphological measurements. The baseline characteristics were comparable between groups. BCVA significantly improved in both groups (letters gained: rasagiline 61.5±18.1 vs placebo 55.3±29.2, p=0.56), but no significant inter-group difference was found at any visit. CRT was stable 3 weeks after surgery onwards, with no inter-group difference. No treatment-emergent AE occurred. Significant prc restoration was observed from 3 weeks to 6 months after surgery, without inter-group difference at either visit. Ellipsoid zone integrity (β=0.517, p=0.008) and foveal bulge (β=0.387, p=0.038) were significant predictors of good final BCVA. In conclusion, perioperative oral treatment with rasagiline 1mg/day for 7 days did not show significant benefits on visual or anatomical outcomes in macula-off RRD patients.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Yu, Siqing; Berger, Lieselotte Erika; Zinkernagel, Martin; Munk, Marion; Wolf, Sebastian and Ebneter, Andreas


600 Technology > 610 Medicine & health




Nature Publishing Group




Andreas Ebneter

Date Deposited:

21 Apr 2020 11:43

Last Modified:

05 Dec 2022 15:37

Publisher DOI:


PubMed ID:





Actions (login required)

Edit item Edit item
Provide Feedback